We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 93.21%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIXC
101
AIxCrypto Holdings Inc
AIXC
$13.9M
$922K 0.01%
22
– –
ABUS icon
102
Arbutus Biopharma
ABUS
$845M
$912K 0.01%
180,582
– –
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$726K 0.01%
4,827
– –
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$668K 0.01%
100,000
– –
BDSI
105
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$620K 0.01%
210,021
– –
IMDZ
106
DELISTED
Immune Design Corp.
IMDZ
$581K 0.01%
148,937
– –
TARA icon
107
Protara Therapeutics
TARA
$213M
$567K ﹤0.01%
7,465
– –
FLGT icon
108
Fulgent Genetics
FLGT
$557M
$548K ﹤0.01%
125,000
– –
AFMD
109
DELISTED
Affimed
AFMD
$520K ﹤0.01%
40,000
– –
FPRX
110
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$422K ﹤0.01%
19,247
– –
TTOO
111
DELISTED
T2 Biosystems, Inc
TTOO
$412K ﹤0.01%
20
– –
CCXI
112
DELISTED
ChemoCentryx, Inc.
CCXI
$292K ﹤0.01%
49,064
– –
NVIV
113
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$255K ﹤0.01%
18
-3
-14% -$69.4K
TENX icon
114
Tenax Therapeutics
TENX
$399M
$171K ﹤0.01%
11
– –
BGMSP
115
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$92K ﹤0.01%
13,253
– –
BTX.WS
116
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$2K ﹤0.01%
20,084
– –
VYGR icon
117
Voyager Therapeutics
VYGR
$182M
– –
-237,014
Closed -$4.88M
TMBR
118
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-40
Closed -$171K
LOXO
119
DELISTED
Loxo Oncology, Inc
LOXO
– –
-96,062
Closed -$8.85M
DMTX
120
DELISTED
Dimension Therapeutics, Inc
DMTX
– –
-1,251,881
Closed -$7.51M
NDRM
121
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-571,667
Closed -$22.2M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Baker Bros. Advisors held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Baker Bros. Advisors's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Baker Bros. Advisors fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Baker Bros. Advisors opened 8 new positions and closed 5 in Q4 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.